You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Chitosan Endoluminal Hemostatic Dressing
SBC: HemCon Medical Technologies Inc Topic: 400DESCRIPTION provided by applicant Perioperative hemorrhage remains the major complication of transurethral and open prostatic surgical procedures Significant blood loss from these procedures causes delayed healing and longer hospitalization which significantly increases the cost of patient care Moreover prolonged urethral catheterization due to significant post operative hematuria is one of ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
A Rapid assay for RNA targeted drugs: Instrumentation Supplement
SBC: NUBAD LLC Topic: 300DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
A Short Instrumented Test of Mobility for Neurological Disorders
SBC: APDM, INC. Topic: NICHDDESCRIPTION provided by applicant APDM is a young company focused on developing and commercializing professional systems using wearable inertial sensors for monitoring of human movement and movement disorders In Phase I we developed the novel Instrumented Stand and Walk test ISAW using APDMandapos s proprietary Opal movement monitors and Mobility Lab system We validated the ISAW by demon ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Reversal of Myocardial Infarction by Localized Stimulation
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTION provided by applicant Heart attacks i e myocardial infarction or MI occur in more than million patients annually Advances in pharmacological therapy have dramatically improved survival following the initial MI Consequently the number of patients with previous MI continues to increase and as a result put in jeopardy millions of patients for development of heart failure I ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II
SBC: BITE TECHNOLOGIES, LLC Topic: 300DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Preclinical development of novel small molecule malaria drugs that overcome drug
SBC: DESIGNMEDIX, INC. Topic: NIAIDDESCRIPTION provided by applicant The worldwide health problem created by malaria has been made more difficult by the spread of drug resistant parasites We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine resistant and chloroquine sensitive malaria This project carries on preclinical development of a drug candidate that has been select ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Advanced Bicycle Helmet Technology for Prevention of Traumatic Brain Injury
SBC: Apex Biomedical Company, LLC Topic: 105DESCRIPTION provided by applicant Traumatic brain injury TBI is an acquired neurological disorder that can cause long lasting disability with limited treatment options Therefore preventative strategies must be emphasized in high risk activities to reduce the individual and societal burden of this pervasive injury Bicycle activities account for of all sports related TBI with ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development, Usability Testing, and Effectiveness Evaluation of the Wraparou
SBC: ACCOUNTABILITY SOLUTIONS, INC. Topic: 104DESCRIPTION provided by applicant The purpose of this Phase II Small Business Technology Transfer STTR project is to complete development and evaluate usability and effectiveness of the Wraparound Team Monitoring System Wrap TMS a web based electronic behavioral health information system EBHIS for the most widely implemented care coordination model in childrenandapos s behavioral healt ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
An innovative in situ cell reprogramming technology for cancer treatment
SBC: QURGEN, INC. Topic: NCIDESCRIPTION (provided by applicant): We invented an innovative protein induced Pluripotent Stem Cells (piPSCs) technology that generates piPSCs from normal fibroblast and cancer cells within 1-week with 90 4% conversion efficiency. Such high conversion efficiency enables us to pioneer an in situ cell reprogramming technology within the cancers of cancer-bearing animals. Instead of generating iPSCs ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health